- Home
- ALNY vs DTE Comparison
ALNY vs DTE Comparison
Compare ALNY & DTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALNY | DTE |
|---|---|---|
| Founded | 2002 | 1903 |
| Country | United States | United States |
| Employees | 115 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Electric Utilities: Central |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.2B | 28.5B |
| IPO Year | 2004 | 2001 |
Fundamental Metrics
Financial Performance| Metric | ALNY | DTE |
|---|---|---|
| Price | $224.00 | $127.67 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 29 | 17 |
| Target Price | ★ $370.55 | $151.89 |
| AVG Volume (30 Days) | 1.2M | ★ 1.6M |
| Earning Date | 10-29-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 3.63% |
| EPS Growth | ★ 206.88 | 3.84 |
| EPS | ★ 2.71 | 1.19 |
| Revenue | $1,037,418,000.00 | ★ $12,607,000,000.00 |
| Revenue This Year | $47.60 | $1.62 |
| Revenue Next Year | $26.59 | $3.39 |
| P/E Ratio | ★ $82.59 | $107.84 |
| Revenue Growth | ★ 22.88 | 18.60 |
| 52 Week Low | $197.81 | $119.68 |
| 52 Week High | $495.55 | $155.75 |
Technical Indicators
Market Signals| Indicator | ALNY | DTE |
|---|---|---|
| Relative Strength Index (RSI) | 40.09 | 47.82 |
| Support Level | $219.54 | $119.68 |
| Resistance Level | $234.00 | $138.24 |
| Average True Range (ATR) | 8.80 | 1.88 |
| MACD | -1.30 | 0.99 |
| Stochastic Oscillator | 20.76 | 87.28 |
Price Performance
Historical ComparisonAbout ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.
About DTE DTE Energy Company
DTE Energy owns two regulated utilities in Michigan that contribute 90% of earnings. DTE Electric serves approximately 2.3 million customers in southeastern Michigan, including Detroit. DTE Gas serves 1.3 million customers throughout the state. In addition, DTE has nonutility businesses and investments including energy marketing and trading, renewable natural gas facilities, and on-site industrial energy projects.